These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Vallejo-Vaz AJ; Ray KK; Ginsberg HN; Davidson MH; Eckel RH; Lee LV; Bessac L; Pordy R; Letierce A; Cannon CP Atherosclerosis; 2019 Sep; 288():85-93. PubMed ID: 31349086 [TBL] [Abstract][Full Text] [Related]
24. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
25. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965 [TBL] [Abstract][Full Text] [Related]
26. Lipid management in ACS: Should we go lower faster? Gencer B; Mach F Atherosclerosis; 2018 Aug; 275():368-375. PubMed ID: 30015301 [TBL] [Abstract][Full Text] [Related]
27. Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events. Lee S; Cannon CP Curr Cardiol Rep; 2018 May; 20(7):55. PubMed ID: 29802475 [TBL] [Abstract][Full Text] [Related]
28. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management. Miname MH; Santos RD Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498 [TBL] [Abstract][Full Text] [Related]
29. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775 [TBL] [Abstract][Full Text] [Related]
30. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597 [TBL] [Abstract][Full Text] [Related]
31. Clinical Pharmacology of Statins: an Update. Ferri N; Corsini A Curr Atheroscler Rep; 2020 Jun; 22(7):26. PubMed ID: 32494971 [TBL] [Abstract][Full Text] [Related]
32. Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target. Sabatine MS; Giugliano RP JAMA Cardiol; 2017 Sep; 2(9):935-936. PubMed ID: 28768310 [No Abstract] [Full Text] [Related]
33. [Hypercholesterolemia and cardiovascular risk]. Sinning D; Landmesser U Dtsch Med Wochenschr; 2023 Aug; 148(16):1025-1032. PubMed ID: 37541292 [TBL] [Abstract][Full Text] [Related]
34. Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients. Okerson T; Patel J; DiMario S; Burton T; Seare J; Harrison DJ J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28314797 [TBL] [Abstract][Full Text] [Related]
35. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394 [TBL] [Abstract][Full Text] [Related]
36. The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Jamialahmadi T; Baratzadeh F; Reiner Ž; Simental-Mendía LE; Xu S; Susekov AV; Santos RD; Sahebkar A Mediators Inflamm; 2021; 2021():9661752. PubMed ID: 34526854 [TBL] [Abstract][Full Text] [Related]
37. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. Gragnano F; Calabrò P Atherosclerosis; 2018 Feb; 269():219-228. PubMed ID: 29407597 [TBL] [Abstract][Full Text] [Related]
38. Evolving Management of Low-Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum. Wilkinson MJ; Lepor NE; Michos ED J Am Heart Assoc; 2023 Jun; 12(11):e028892. PubMed ID: 37260036 [TBL] [Abstract][Full Text] [Related]
39. Beyond Statins: Who and When to Prescribe? Ganda O Curr Diab Rep; 2018 Oct; 18(11):126. PubMed ID: 30324282 [TBL] [Abstract][Full Text] [Related]